Medgenics Reports Sale of Common Stock by Director
December 04 2013 - 7:30AM
Business Wire
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the
Company), the developer of BiopumpTM, a novel technology for the
sustained production and delivery of therapeutic proteins in
patients using their own tissue, announces that on December 2, 2013
and December 3, 2013, the Company was informed by Dr. Eugene Bauer,
a Director of the Company, that he sold a total of 20,000 shares of
common stock on the open market on those days at an average price
of $6.30 per share.
Following this sale, Dr. Bauer owns 195,874 shares of common
stock representing approximately 1.1 percent of the issued share
capital. Dr. Bauer also has the right to purchase up to 78,571
shares of common stock pursuant to warrants and options previously
granted (in aggregate Dr. Bauer’s shares of common stock, warrants,
and options represent 274,445 shares of common stock which
represent approximately 1.5 percent of the issued share
capital).
This announcement is being made pursuant to the London Stock
Exchange’s AIM Rules for Companies admitted to trading on the AIM
market.
About Medgenics
Medgenics is developing and commercializing Biopump™, a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own tissue for the treatment of a range of chronic diseases
including anemia, hepatitis, among others. For more information,
please visit www.medgenics.com
Medgenics, Inc.John Leaman,
CFOjohn.leaman@medgenics.comorLHAAnne Marie
Fields212-838-3777afields@lhai.com@LHA_IR_PRorAbchurch
CommunicationsJoanne Shears / Jamie Hooper / Harriet Rae+44 207 398
7718harriet.rae@abchurch-group.comorOriel Securities (NOMAD &
Broker)Jonathan Senior / Giles Balleny+44 207 710 7617
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Aug 2023 to Aug 2024
Real-Time news about Aevi Genomic Medicine Inc (NASDAQ): 0 recent articles
More Medgenics, Inc. News Articles